Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：独立董事关于公司2022年的对外担保情况的专项说明
Regulatory Filings
2023-04-25 Chinese
美迪西：2022年社会责任报告
Environmental & Social Information Classification · 95% confidence The document is titled "2022 年度社会责任报告" which translates to "2022 Annual Social Responsibility Report". It details the company's practices and performance in economic, environmental, social, and governance responsibility areas for the year 2022. The content includes CEO's message, company overview, governance structure, risk management, ESG management, quality assurance, and innovation in R&D platforms. It references standards such as GRI Standards and ISO 26000 related to sustainability and social responsibility reporting. The document is comprehensive and focused on Environmental, Social, and Governance (ESG) factors rather than financial results or corporate governance changes. Therefore, it fits the category of Environmental & Social Information (Code: SR).
2023-04-25 Chinese
美迪西：2022年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制评价报告' which translates to '2022 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2022, including financial and non-financial internal control defects, their identification, and remediation status. The document is a detailed report on internal control evaluation, which is typically part of audit-related disclosures but is not a full annual report (10-K) or an audit opinion alone. It is not an announcement or a brief notice but a substantive report on internal control evaluation. This fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. The document length is 4111 characters, which is substantive but not extremely long, consistent with an internal control evaluation report. Therefore, the classification is AR with high confidence. FY 2022
2023-04-25 Chinese
美迪西：关于向银行申请授信额度的公告
Capital/Financing Update Classification · 100% confidence The document is a public announcement by Shanghai Medicilon Inc. regarding the company's board approval to apply for a bank credit facility up to 1.1 billion RMB. It details the credit types, terms, and authorization for management to sign related legal documents. There is no financial report, earnings data, or regulatory certification. The content is an update on financing activities, specifically about credit/loan facilities. The document length is short (731 characters) and it is clearly an announcement of a financing update, not a full financial report or audit. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-04-25 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司使用剩余超募资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a formal opinion from the sponsor (广发证券股份有限公司) regarding the use of remaining over-raised funds by Shanghai Medicilon Inc. to permanently supplement working capital. It references regulatory guidelines on the management and use of raised funds, details the original fundraising, investment projects, and the plan to use surplus funds. The document includes the sponsor's verification and approval opinions, board and supervisory committee meeting approvals, and mentions the need for shareholder meeting approval. The document is a regulatory compliance and verification statement related to capital use, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive content and analysis about the use of funds and regulatory compliance. It fits best under Capital/Financing Update (CAP) as it updates on the use of capital raised and compliance with fundraising regulations.
2023-04-25 Chinese
美迪西：董事会审计委员会2022年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as a report on the 2022 annual performance of the Board Audit Committee of Shanghai Medicilon Inc. It details the committee's activities, meetings, oversight of external and internal audits, review of financial reports, internal control guidance, and coordination with auditors. The content focuses on the audit committee's duties and their fulfillment over the year 2022. It is not a full annual report (10-K) or standalone audit report (AR) but a specific committee report on audit committee activities and performance. This type of document aligns with an Audit Report / Information (AR) category, as it is a standalone report related to audit committee activities and audit oversight, not the full company annual report or other categories. The document length is 1765 characters, which is short but contains substantive content about audit committee work, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2022
2023-04-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.